Pazopanib in Treating Patients With Recurrent Glioblastoma

PHASE2CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

December 31, 2008

Study Completion Date

December 31, 2008

Conditions
Adult Giant Cell GlioblastomaAdult GlioblastomaAdult GliosarcomaRecurrent Adult Brain Tumor
Interventions
DRUG

pazopanib hydrochloride

Given orally

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (9)

10021

Memorial Sloan-Kettering Cancer Center, New York

15232

University of Pittsburgh, Pittsburgh

20814

National Cancer Institute Neuro-Oncology Branch, Bethesda

27710

Duke University, Durham

53792

University of Wisconsin, Madison

77030

MD Anderson Cancer Center, Houston

90095

University of California Los Angeles, Los Angeles

94115

University of California San Francisco, San Francisco

02115

Dana Farber Cancer Institute, Boston

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00459381 - Pazopanib in Treating Patients With Recurrent Glioblastoma | Biotech Hunter | Biotech Hunter